STOCK TITAN
  1. Home
  2. News
  3. ORIC

ORIC Pharmaceuticals Inc - ORIC STOCK NEWS

Welcome to our dedicated news page for ORIC Pharmaceuticals (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on ORIC Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ORIC Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ORIC Pharmaceuticals's position in the market.

News
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
Rhea-AI Summary
ORIC Pharmaceuticals announces the dosing of the first patients across three expansion cohorts in the Phase 1b trial of ORIC-114 for mutated NSCLC, with promising Phase 1b data reported and plans to release updated data in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
clinical trial
-
News
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
ORIC Pharmaceuticals presents promising preclinical data on ORIC-944 and ORIC-613 at the 2024 AACR Annual Meeting, highlighting their potential as best-in-class inhibitors for prostate cancer and TRIM37-high tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
clinical trial
-
News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. granted 84,800 non-qualified stock options and 14,400 restricted stock units to new non-executive employees. The grants were part of the 2022 Inducement Equity Incentive Plan, with specific vesting schedules. The inducement grants were approved by the Compensation Committee of the Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
News
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (ORIC) will be participating in investor conferences in April, including the 23rd Annual Needham Virtual Healthcare Conference and Stifel Virtual Targeted Oncology Forum. The company will present a company overview and participate in a fireside chat to discuss its focus on developing treatments for therapeutic resistance mechanisms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences
-
News
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. reported positive Phase 1b data supporting best-in-class profiles for ORIC-944 and ORIC-114, with plans for further advancement and combination studies. The company strengthened its cash position with $210 million from private placements, ensuring funding into late 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.47%
Tags
earnings
-
News
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. will present a company overview at the Leerink Partners Global Biopharma Conference on March 13, 2024. The focus is on developing treatments for therapeutic resistance in oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
News
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. announces multiple abstracts accepted for presentation at the 2024 AACR Annual Meeting. ORIC-944, a potent PRC2 inhibitor, shows promise in prostate cancer treatment. ORIC-613, a PLK4 inhibitor, demonstrates synthetic lethality in TRIM37-high cancer models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
-
News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. granted 3,600 non-qualified stock options and 600 restricted stock units to a new non-executive employee. The grants were made under the 2022 Inducement Equity Incentive Plan, with specific vesting schedules. The inducement grants were approved by the Compensation Committee and were a material inducement to employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
none
-
News
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. will participate in a fireside chat at the Citi 2024 Virtual Oncology Leadership Summit on February 21, 2024. The company focuses on developing treatments for therapeutic resistance in oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
conferences
News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. granted non-qualified stock options and restricted stock units to new non-executive employees as part of the 2022 Inducement Equity Incentive Plan. The options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date, with vesting periods specified. The grants were approved by ORIC’s Compensation Committee and were granted as a material inducement to employment in accordance with Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock ORIC logo
ORIC Pharmaceuticals Inc

Nasdaq:ORIC

ORIC Rankings

#2718 Ranked by Market Cap
#86 Ranked by Stock Gains
N/A Ranked by Dividends

ORIC Stock Data

660.28M
37.08M
9.53%
88.37%
12.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About ORIC

oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.